Maintenance in the property management world is still pretty analogue. Soundsensing aims to change that. At Soundsensing, we are building a platform for providing intelligence and insights to customers in the property management market, through sensors and machine learning. We gather data from any source: our own sensors developed in-house, existing sensors, and other data streams, before we turn the data into actionable insights through condition monitoring and predictive maintenance. We are developing technologies using machine learning, IoT and cloud computing. These are not buzzwords to us, and we need people capable of- and interested in building good solutions for these technologies. We are dedicated to solving hard problems - and we are growing rapidly.

KAHU aims to close a persistent gap in maritime visibility - the inability to continuously track vessels not transmitting AIS (Automatic Identification System) data. AIS can be switched off, spoofed, or absent, creating blind spots exploited by illegal fishing, shadow fleets, and other high-risk actors. The AIS market is also dominated by a few providers, limiting access and transparency. This affects not only maritime safety and security but also the monitoring of ocean environments. We address this by building the first real-time, crowdsourced radar detection network for the ocean. Our onboard software connects to existing vessel radar, collects radar echoes, and streams them securely to the cloud using low-bandwidth protocols. There, echoes are linked into vessel tracks and fused with AIS, satellite imagery, and other data layers to produce a continuous, sea-level view of vessel movements, enabling comprehensive visibility over human activity at sea and supporting timely, informed action.

Rift Labs AS is a Norwegian based LED technology company with a unique hardware & software-competence. The company was founded in 2010 by serial entrepreneur and tech wizard Morten Hjerde (current CTO of the company, and also founder of Link Mobility), with a vision to create amazing creative lighting. Since inception we’ve been a technology pioneer and innovator within the photo and video industry, developing our own, proprietary and patented LED lighting technology. We have a large installed base with more than 45.000 units sold to date, and our products are used and loved by photographers and video producers all over the world.

At Fitjeans, we're on a mission to share the great feeling of perfect fitting jeans to as many people as we can. We want our customers to feel confident and comfortable in their jeans, not having to make any compromise in looks or well being while wearing our jeans. We're a Norwegian e-commerce company that are selling tailored jeans to over 127 countries from our warehouse in Berlin. From our start in 2018, we’ve scaled rapidly, achieving over 500 000 happy customers and now exceeding 100 million NOK in annual turnover. We’re a team that values creativity, collaboration, and a drive to constantly improve. If you’re passionate about pushing boundaries in e-commerce and making a real difference in our company, we invite you to explore opportunities at Fitjeans.

Nexro is an early phase startup with the mission of empowering the music industry. We are developing our predictive AI analytics to give the music professionals true insights from music trends. We gather data from streaming platforms, social media, radio stations and music consumption to deliver real-time trends predictions so that labels, publishers, marketing, promotion and other music industry professionals can take their operations to the next level.

OncoImmunity is a bioinformatics company providing unique machine-learning software to identify tumor-specific mutations that can be targeted by a patient’s own immune system (known as neoantigens). The OncoImmunity solution is important because recent breakthroughs in the field of Immuno-Oncology (I-O) such as the development of checkpoint inhibitors and personalized cancer vaccines, clearly demonstrate that a patient’s immune system can be harnessed to successfully treat cancer. The cost of identifying tumor-specific mutations in a patient’s cancer using next-generation sequencing (NGS) is now trivial and this technology will be key to enabling truly personalized immunotherapies to be developed in a technically and economically feasible manner. However, the remaining challenge that currently limits the field, and which is addressed by the OncoImmunity solution, is predicting which tumor-specific mutations can stimulate a patient’s immune system i.e. are immunogenic. Using NGS data as input, the OncoImmunity software enables accurate patient selection for cancer immunotherapy and can identify optimal targets for personalized cancer vaccines & cell therapies in a clinically actionable time frame. Beginning from this first product offering, OncoImmunity has the vision to become the world’s leading provider of software to guide cancer immunotherapy to improve survival rates for cancer patients. To achieve this OncoImmunity has assembled a growing team of world-class bioinformaticians, data scientists, and software engineers; developing its cutting-edge machine-learning technology that will help fulfill the promise of immunotherapy in the fight against cancer. OncoImmunity’s technology will disrupt the I-O field by offering regulatory-compliant prediction software on a software-as-a-service basis (SaaS). This will allow big pharma, biotechnology, and immunotherapy companies of any size to access OncoImmunity’s cutting-edge prediction software. The company is headquartered in an ideal scientific and entrepreneurial ecosystem to develop its technology at the Oslo Cancer Cluster Incubator; adjacent to the Institute for Cancer Research and the Norwegian Radium Hospital. OncoImmunity is a privately held company, founded in 2014 by experienced bioinformatics scientists (Dr. Trevor Clancy and Professor Eivind Hovig), and an experienced immunologist with a business development background (Dr. Richard Stratford). The company is backed by private financing from the Norwegian Radium Hospital Research Foundation, the Norwegian Cancer Society, STARTUPLAB, and Grotmol Solutions, in addition to a number of private software investors. The company is also supported by grants awarded from the Norwegian Research Council, Innovation Norway, and the EU. The company has already established both national and international collaborations and pilot projects to develop further proof-of-concept data and validate its software.

Business Angels Norway is the only umbrella assocation for regional or industry-specific angel groups in Norway. We are a co-founder of NordicBAN, the Nordic-Baltic assocation for business angels. We have ca 10 angel groups all over Norway, with >500 business angels total. We are an interest assocation, working for the interests of angel groups and business angels in general. We are part of several international initiatives and projects, incl the Nordic Angel Program where we need YOU!

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Kindly is one of Europe’s leading chatbot providers specializing in the development of artificial intelligence and automation solutions for customer service and communication. The company offers a platform that combines advanced machine learning techniques and natural language processing (NLP) to enhance the customer experience and improve the efficiency of customer service processes.

Avidly is a fully integrated MarTech service provider covering every aspect of the customer experience. We´re 3 x Global HubSpot Partner of the Year and as an Elite HubSpot Solutions Partner, we share the tool with our customers to consistently help them grow their businesses. We are a one-stop-shop for digital marketing and sales. We help companies grow by providing them technical and creative solutions that makes a difference. Together with our clients we always strive to find new ways to growth.

Payr is the next generation payment platform empowering consumers to pay invoices in flexible and smart ways. Our customers can pay any invoice using their bank account, debit or credit card, or digital wallets, saving them time and money. Payr also improves invoice payments by providing truly independent price and quality comparison, enabling simple and fast switching to providers that offer greater value to our customers.Our first product launched Q3 2017 and can be found in App Store We have an experienced team of 11 people, with backgrounds from others startups and from leading Tech, UX, and advertising consultancy companies such as Making Waves and Dinamo, as well as a strong board of directors with backgrounds from Fintech, legal and IT at Nordea, Mastercard, Selmer Law, mCash and Itera.Even if we have an experienced team, we want everyone to be able to learn new things, so you get a lot of responsibility but also a lot of opportunities for improving and learning at Payr. We have international ambition, expanding to the Nordics next year. So you could say we have a pretty aggressive growth strategy as well. This makes most days hectic, but fun.We have 5 exits from other startups in our management team, so many of us have experience with doing this from before. Therefore, we try not to spend energy on stuff we know is going to be a waste of time. You could say we aim to have a professional way of running things, with systems to help everything run smoothly. Although we have high expectations for each other and our product, we also have a quite friendly environment, including a snoring office dog.

Based in Norway, Recharge Health is a team of innovators dedicated to unlocking the full potential of the human body. Through collaboration with doctors and researchers worldwide, we've created FlexBeam, a revolutionary recovery device utilizing targeted infrared light therapy. Our mission is to bring the power of infrared light therapy into every home. More on FlexBeam: FlexBeam is the most powerful infrared therapy device of its kind. This non-pharmaceutical, non-invasive solution is already making a significant impact on the lives of many. With over 40,000 satisfied customers worldwide and endorsements from notable, global athletes, this wearable recovery device is changing the game of athletic recovery and health optimization. Developed with NASA-inspired technology, FlexBeam uses infrared light therapy to deliver powerful wavelengths of red (610-650nm) and near-infrared (800-850nm) light at up to 110mW/cm2, and a total optical power output of 5.5W. This powerful and targeted light stimulates your cells to produce more energy – so you can repair muscle, relieve pain, and recover faster. Learn more about our company here: https://www.youtube.com/watch?v=iEv3BimOCS8

B’ZEOS develops novel, flexible, and home-compostable films based on seaweed extracts which can replace conventional and bio-based single-use plastic films in food-contact applications. B’ZEOS’ solution will contribute to reduce the use of non- or hardly recyclable plastic materials for single-use food packaging, thus reducing CO2 emissions. We are a team of 8 people with complementary backgrounds. One engineer in environment, two material scientists, one graphic designer, one supply chain analyst, one quality engineer advisor, one PR and marketing advisor and one CFO advisor.   Each of us are concerned by environmental issues and wanted to contribute to make a change.   We have joined this project because we are all fed up with:    - Contamination of world's drinking water with plastic fibres   - Seeing marine animals dying because of our plastic trash   - Increase of plastic packaging around fresh aliments   - Increase in plastic debris along the coast   - Both burning plastic and sending plastic to landfills   - Finding plastic while making with our kids sand castles   - Contamination with the chemicals in plastic. These chemicals are said to cause obesity, on-set puberty, and even cancer.   - Direct contamination of our kids by chewing various objects in plastic.   - Being exposed to plastic every single day and not having the chance to choose an alternative   We, at B’ZEOS and as consumers, believe in a sustainable alternative to current plastic and we have been working on the elaboration of a sustainable alternative without forcing the consumer to change dramatically his habits.

Signicat is a pioneering, pan-European digital identity company with a unrivalled track record in the world’s most advanced digital identity markets. Its digital identity platform incorporates the most extensive suite of identity verification and authentication systems in the world, all accessible through a single integration point. The platform supports the full identity journey, from recognition and on-boarding, through login and consent, to making business agreements which stand the test of time.

Today Mobility provides consumer-centric first and last mile logistics to the automotive industry. Our drivers pick up and deliver cars to and from workshops and dealerships all over Sweden whether it be for a Test Drive, New/Used car delivery or for a routine Workshop visit. So far we've delivered over 150,000 cars, and are working with Sweden's largest car manufacturers and dealers as they transition to online sales and service channels. Our vision is simple - to make car ownership simpler, more convenient and sustainable.